

The hepatic stem cell line

CERTIFICATE OF ANALYSIS

DIFFERENTIATED HEPARG[®]-NS CRYOPRESERVED

Catalog number: HPR116NS

Batch number: HNS1004

For in vitro and research use only

| | |
|--|---|
| 1. PRODUCT DESCRIPTION | 2 |
| 2. PRODUCT CHARACTERIZATION | 2 |
| 3. CONDITIONS OF CELL SEEDING | 5 |
| 4. CONDITIONS OF STORAGE AND DELIVERY | 5 |
| 5. COMPANION PRODUCTS | 5 |
| 6. OTHER OFFERING OF THE HEPARG [®] CELLS | 6 |
| 7. VISA BATCH RELEASE | 6 |

For more information, visit
www.HepaRG.com

LIMITED USE LICENSE

HepaRG[®] cells are patented and their use is strictly limited; consider the cells as a single-use, disposable product that must be destroyed upon conclusion of a study or experiment. Propagating, reproducing, cloning, subcloning or any other use of the cells following the conclusion of a study is prohibited. Use of the cells to produce or manufacture commercial products for general sale or for use in the manufacture of products intended for general sale is prohibited. Transfer of the cells to anyone not employed within the same organization, whether for financial benefit or not, is prohibited. **If you are unwilling to accept the terms of this LIMITED USE LICENSE, do not ORDER or use them, and immediately return the cells for credit. Violators of this Limited Use License will be prosecuted to the fullest extent of the law.**

1. PRODUCT DESCRIPTION



| | | |
|---|--|---------|
| Species | Human | |
| Origin | Liver tumor of a patient suffering from hepatocarcinoma and hepatitis C infection | |
| Safety data | Absence of hepatitis B, hepatitis C and HIV1 viruses checked by PCR on the cell suspension. <i>Caution: although controls are performed, human material has to be considered as potentially dangerous. Take maximum care in order to protect yourself and your colleagues.</i> | |
| Biosafety level | Level 2, as recommended in the CDC-NIH Manual, Biosafety in Microbiological and Biomedical Laboratories, 5th edition, N°21-1112 Revised December 2009 | |
| Description | HepaRG [®] cells, catalog number HPR116NS are cryopreserved after differentiation using a proprietary process developed by Biopredic International. HPR116NS is a new format of the HPR116 with a freezing process that allows direct thawing and seeding of cryopreserved differentiated cells without the need for post-thaw washing, centrifugation and counting steps. A few days after thaw and culture, the cells will form a coculture of hepatocytes and of biliary epithelial-like cells. Gripon P. <i>et al. Proc. Natl. Acad. Sci. 99, 15655-15660, 2002.</i> | |
| Packaging | HPR116NS: 0.5 mL vial with $\geq 8 \times 10^6$ viable cells | |
| CYP genotyping data | Obtained in collaboration with N. Picard at Limoges hospital (France) using a validated TaqMan allelic discrimination assay (ABI PRISM 7000 Sequence Detection System, Applied-Biosystems). | |
| SNPs description | CYP2D6 | |
| SNPs: Single Nucleotide Polymorphisms wt: wild- type | *2 (2850C>T) | *2/wt |
| | *3 (2549delA) | wt/wt |
| mut: mutation **: wt=G T=minor allele in Caucasians | *4 (1846G>A) | wt/wt |
| | *7 (2935A>C) | wt/wt |
| | *10 (100C>T) | wt/wt |
| | CYP3A4 | |
| | *1B (392G>A) | wt/wt |
| | OATP1B1 (=OATP2) | |
| | *5 (521T>C) | wt/*5 |
| | OATP1B3 (=OATP8) | |
| | 334T>G | wt/wt** |
| | MRP2 | |
| -24C>T | wt/wt | |
| 1249G>A | wt/mut | |
| 3972C>T | wt/mut | |

2. PRODUCT CHARACTERIZATION

. Cell production

| | |
|-----------------------|----------------------|
| Cell freezing | On December 17, 2015 |
| Passage number | Between 13 and 20 |

. Cell controls

| Criteria | Method | Specification | Accepted |
|--|---|--|---------------------------|
| Number of viable cells per vial | Microscopic observation | $\geq 8 \times 10^6$ | Yes (9.3×10^6) |
| Post-thaw viability (Day 0)^a | Trypan blue exclusion test | $\geq 80 \%$ | Yes (96 %) |
| Cell density^b | Microscopic observation 6 hours after thawing and seeding cells | $\geq 85 \%$ | Yes (see picture) |
| | |  <p>X 100 – After thawing of cells and 6 hours of culture in the HepaRG[®]-NS Thawing/Plating medium using ADD411</p> | |
| Cell morphology | Microscopic observation 4 days after thawing and seeding cells, 50 % of typical hepatocyte-like cells are organized in well-delineated clusters with bright canaliculi-like structures. |  <p>X 100 – After thawing of cells in the HepaRG[®]-NS Thawing/Plating medium using ADD411, and 72 hours in the HepaRG[®]-NS Maintenance/Metabolism Medium using ADD421</p> | |
| Mycoplasma detection | Biochemical test | Negative | Yes (negative) |
| Microbial sterility | Under standard use conditions | No microbial growth detectable | Yes (undetectable) |

^a: After thawing, differentiated HepaRG[®]-NS viability is determined by Trypan blue (0.05% in PBS) exclusion test at 10 min post-thaw.

^b: Differentiated HepaRG[®]-NS are seeded on collagen-coated multi-well culture plates in the HepaRG[®]-NS Thawing/Plating medium using ADD411, according to Biopredic's description and use guide for thawing, culture and use of cryopreserved differentiated HepaRG[®]-NS (fduHPR116NS).

. Vmax value of Phase I dependent activities (nmole/h/million cells)

| Activity | Enzyme | Method | Specification | Result |
|--|----------|---|---------------|------------|
| Phenacetin O-deethylase activity | CYP1A2 | After thawing of cells in the HepaRG [®] -NS Thawing/Plating medium using ADD411, cells were incubated in suspension for 1 hour at 37°C with the following test substrates: - phenacetin (200µM), - midazolam (50µM), - bupropion (100µM), - dextrometorphan (100µM). Metabolites formed were measured by LC-MS/MS. | ≥ 0.2 | 0.2 |
| Midazolam 1' hydroxylase activity | CYP3A4/5 | | ≥ 1 | 1.8 |
| Bupropion hydroxylase activity | CYP2B6 | | ≥ 0.05 | 0.2 |
| Dextrometorphan O-demethylase activity | CYP2D6 | | ≥ 0.05 | 0.1 |

Activities are expressed as nanomole of metabolite formed/h/million cells. To convert to pmole of metabolite/min/million cells multiply the results by 16.66.

. Induction of metabolic activity

| Inducer | Enzyme | Assay | Method | Fold induction* activity of treated cells/activity of control cells | |
|--------------------|----------|----------------------------|--|--|-----------|
| | | | | Specification | Result |
| Omeprazole, 50µM | CYP1A2 | Phenacetin O-deethylation | After thawing of cells in the HepaRG [®] -NS Thawing/Plating medium using ADD411, and 48 hours in the HepaRG [®] -NS Pre-induction/Tox medium using ADD431, cells were incubated for again 48 hours in the HepaRG [®] -NS Serum Free Induction medium using ADD451 with the test inducers. Cells were then incubated with the test substrates : | ≥ 3.5 | 9 |
| Phenobarbital, 1mM | CYP2B6 | Bupropion-hydroxylation | - for 2 hours with midazolam (50µM) | ≥ 3 | 7 |
| Rifampicin, 10µM | CYP3A4/5 | Midazolam 1'-hydroxylation | - for 4 hours with bupropion (100µM), - for 5 hours with phenacetin (200µM). The formation of metabolites was measured by LC-MS/MS. | ≥ 4 | 19 |

* The fold induction in CYP1A2, CYP2B6 and CYP3A4/5 activity was determined as a measure of specific metabolite formation relative to vehicle control cells (un-induced).

. Vmax value of uptake transporter activities (pmole/min/million cells)

| Substrate | Transporter | Method | Mean value +/- confidence interval of 90%** |
|--------------------------------------|-------------|---|---|
| [³ H] MPP+ 250µM | OCT | After thawing, cells were incubated in suspension at 37°C in uptake medium with either [³ H]MPP+, or [³ H]taurocholate for 3 minutes. The uptake transporter activity (Vmax) was measured as cell-associated radioactivity with a liquid scintillation counter and expressed in pmol/min/million cells. *Taurocholate is also a substrate of OATP. | 307 +/- 23 |
| [³ H] Taurocholate* 25µM | NTCP | | 12 +/- 0.9 |

** Obtained from 30 batches tested

3. CONDITIONS OF CELL SEEDING

With one vial of HPR116NS batch HNS1004

| Cell culture support | Cell seeding volume per well (mL) | Total volume of cell suspension (mL) | Maximum number of wells to be seeded |
|----------------------|-----------------------------------|--------------------------------------|--------------------------------------|
| 6 well plate | 2 | 9.3 | 4 |
| 12 well plate | 1 | 11.6 | 11 |
| 24 well plate | 0.5 | 9.7 | 19 |
| 48 well plate | 0.2 | 11.6 | 58 |
| 96 well plate | 0.1 | 12.9 | 129 |

Note that properly thawed cells will be in a suspension volume of 8mL so these figures are inclusive of that; for example when using 96 well plates with this Lot, 4.9 mL of working Thawing/Plating Media should be added to achieve a total volume of 12.9 mL.

4. CONDITIONS OF STORAGE AND DELIVERY

STABILITY, STORAGE, DELIVERY

| | |
|------------------------------|--|
| Stability and Storage | 5 years in liquid nitrogen |
| Delivery | In dry ice or in liquid nitrogen If in dry ice, ensure shipment time did not exceed 48 hours |
| Use | Follow description and use guide for thawing, culture and use of cryopreserved differentiated HepaRG [®] -NS (fduHPR116NS). |

5. COMPANION PRODUCTS

CULTURE MEDIA*

| Denomination | Catalog number |
|---|----------------|
| HepaRG [®] -NS Thawing/Plating Medium Supplement with corticoids, to be combined with 100 mL of Basal medium w/o phenol red | ADD411 |
| HepaRG [™] -NS Maintenance/Metabolism Medium Supplement with corticoids, to be combined with 100 mL of Basal medium w/o phenol red | ADD421 |
| HepaRG [®] -NS Pre-induction/Tox Medium Supplement with corticoids, to be combined with 100 mL of Basal medium w/o phenol red | ADD431 |
| HepaRG [®] Serum-free Induction Medium Supplement with corticoids, to be combined with 100 mL of Basal medium w/o phenol red | ADD451 |

*For details on use of supplements, consult the Description and Use Guide thawing, culture and use of cryopreserved differentiated HepaRG[®]-NS (fduHPR116NS)

CULTURE SUPPORT


| Denomination | Catalog number |
|---------------------------------------|----------------|
| 6-well plate coated with collagen I* | PLA135 |
| 12-well plate coated with collagen I* | PLA138 |
| 24-well plate coated with collagen I* | PLA137 |
| 48-well plate coated with collagen I* | PLA139 |
| 96-well plate coated with collagen I* | PLA136 |

*BPI proprietary coating process to ensure proper seeding and culture of the HPR116

6. OTHER OFFERING OF THE HEPARG[®] CELLS

| Denomination | Catalog number |
|--|----------------|
| Undifferentiated, cryopreserved HepaRG [®] cells for on-site propagation and differentiation. Please see on our HepaRG [®] web site www.heparg.com for the conditions to obtain the cell line. | HPR101 |
| HepaRG [®] differentiated cells, cryopreserved after differentiation using a proprietary process developed by Biopredic International. | HPR116 |
| HepaRG [®] undifferentiated cells, cryopreserved with a sufficient quantity of culture medium for production of 50 plates within a 6 month period of time. | KIT901 |

7. VISA BATCH RELEASE

| Name | Signature | Date |
|---|--|----------------------|
| Sandrine Camus, Product Chief |  | On February 05, 2016 |
| Belkacem Bouaita, Quality Control Manager |  | On February 05, 2016 |